What brand drug combinations are available for the treatment of chronic obstructive pulmonary disease (COPD) in the Indian market?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 7, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Available Brand Drug Combinations for COPD Treatment in the Indian Market

I cannot provide specific brand names available in the Indian market as the evidence provided does not contain information about commercial brand names or market availability in India.

Evidence-Based Drug Combinations for COPD Management

The most effective drug combinations for COPD treatment are triple therapy (ICS/LABA/LAMA) and dual bronchodilator therapy (LABA/LAMA), with selection based on exacerbation history and symptom burden. 1, 2

Triple Therapy Combinations (ICS/LABA/LAMA)

Triple inhaled therapy improves lung function, symptoms, and health status (Evidence A) and reduces exacerbations (Evidence B) compared with ICS/LABA or LAMA monotherapy. 1

  • Fixed-dose triple combinations containing fluticasone furoate/vilanterol/umeclidinium or beclometasone/formoterol/glycopyrronium significantly reduce exacerbation rates, improve dyspnea scores, lung function, and quality of life better than dual therapy comparators 3

  • Triple therapy is indicated for COPD patients in Groups C and D - those with frequent exacerbations (≥2 per year or ≥1 requiring hospitalization) or elevated peripheral eosinophil counts 2, 3

  • Single-inhaler triple therapy (SITT) offers superior convenience with once-daily dosing and lower error rates compared to multiple-device regimens 4, 5

Dual Bronchodilator Combinations (LABA/LAMA)

LABA/LAMA combination is the most preferred initial bronchodilator therapy for patients with severe COPD due to superior patient-reported outcomes, better exacerbation prevention, and lower pneumonia risk compared to ICS/LABA combinations. 6

  • Available LABA/LAMA fixed-dose combinations include: indacaterol/glycopyrronium, vilanterol/umeclidinium, formoterol/aclidinium, and olodaterol/tiotropium 7

  • LABA/LAMA combination improves symptoms and health status, is more effective than long-acting bronchodilator monotherapy for preventing exacerbations, and decreases exacerbations to a greater extent than ICS/LABA combination 1, 6

ICS/LABA Combinations

  • An ICS combined with a LABA is more effective than individual components in improving lung function and health status and reducing exacerbations in patients with moderate to very severe COPD and exacerbations (Evidence A) 1

  • LABA/ICS combinations may be first-choice initial therapy for patients with features suggesting asthma-COPD overlap or high blood eosinophil counts 6

  • Critical caveat: Regular treatment with ICS increases the risk of pneumonia, especially in those with severe disease (Evidence A) 1

Device Technology Available in India

  • Synchrobreathe™ (Cipla Ltd, India) is a breath-actuated pressurized metered-dose inhaler available with a wide range of drug combinations 8

  • Studies show 68.19% of patients used Synchrobreathe™ without error compared to 56.21% with conventional pMDI, and 92% found it easy to understand and use 8

  • This device resolves coordination issues by mechanically actuating the dose in synchrony with inspiration at low inhalation effort 8

Treatment Algorithm Based on Disease Severity

Mild COPD (Group A)

  • Short-acting beta-agonists (SABA) or short-acting muscarinic antagonists (SAMA) as needed for intermittent symptom relief 6
  • No drug treatment if asymptomatic 6

Moderate COPD (Group B)

  • Single long-acting bronchodilator (either LABA or LAMA) as initial therapy 6
  • Escalate to dual LABA/LAMA therapy for persistent breathlessness on monotherapy 6

Severe COPD (Groups C and D)

  • LABA/LAMA combination as foundation therapy 2, 6
  • Add ICS (triple therapy) if ≥2 exacerbations per year, ≥1 hospitalization for exacerbation, or elevated eosinophils 2

Indian Context Considerations

The OAD population in India may benefit from early optimization to single-inhaler triple therapy characterized by high burden of exacerbating OAD, nonsmoker COPD, and asthma-COPD overlap. 5

  • Poor adherence to inhaler therapy is a frequent challenge in India, making single-inhaler combinations particularly valuable 5

  • Better treatment options that optimize symptom control, improve quality of life, reduce exacerbation risk, and improve adherence are desired in the Indian setting 5

Critical Pitfalls to Avoid

  • Never add a second LAMA to triple therapy containing umeclidinium or glycopyrronium, as this increases adverse effects without clinical benefit 4

  • Avoid all beta-blocking agents, including ophthalmic preparations, as they antagonize LABA components and worsen bronchodilation 1, 4

  • Monitor closely for anticholinergic side effects including dry mouth, urinary retention, constipation, and blurred vision, particularly in elderly patients on multiple medications 4

  • Assess for pneumonia risk with ICS-containing regimens: monitor for new or worsening dyspnea, fever, increased sputum production or purulence 4

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

2
Guideline

Management of Moderate to Severe COPD

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

4
Guideline

Trelegy Use in COPD Patients with Parkinson's Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

6
Guideline

COPD Management with Medications

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What are the recommended drug combinations (LABA (long‑acting β2‑agonist) + LAMA (long‑acting muscarinic antagonist), LABA + ICS (inhaled corticosteroid), and triple therapy) for adult patients with stable chronic obstructive pulmonary disease (COPD) in India?
What are the recommended treatment guidelines for Chronic Obstructive Pulmonary Disease (COPD) as per the 2025 guidelines?
What is the recommended inhaler treatment for a patient with Chronic Obstructive Pulmonary Disease (COPD)?
What are examples of Long-Acting Muscarinic Antagonist (LAMA) inhalers?
What fixed‑dose inhaler combinations (brand and generic names) are available for chronic obstructive pulmonary disease treatment in India, and what are their recommended dosing regimens?
How should I assess and manage an adult with persistent anxiety, ensuring no acute medical, substance, or safety concerns, and what are the first‑line treatment options?
In an agitated patient with pneumonia, severe respiratory acidosis and significant hypoxemia, is elective intubation the best management over BiPAP?
What are basic retinopathy and retinal vascular changes, and how should they be evaluated and managed?
In a 33-year-old female with a perforated left tympanic membrane and a cloudy right tympanic membrane, who is currently using ofloxacin 0.3% ear drops three times daily after prior use of neomycin/polymyxin B/hydrocortisone oil, what is the best next step in management?
In an adult emergency department patient with right upper quadrant pain, fever, leukocytosis, and a history of gallstone disease, what is the first‑line imaging study to evaluate for acute cholecystitis?
What symptoms and criteria support a diagnosis of generalized anxiety disorder in an adult with persistent worry after ruling out medical, substance, and safety causes?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question